Oberotatug Biosimilar – Anti-DEC-205 mAb – Research Grade

The Structure and

Activity of Oberotatug Biosimilar – Anti-DEC-205 mAb – Research Grade

Oberotatug Biosimilar – Anti-DEC-205 mAb – Research Grade is a monoclonal antibody that has been designed and produced to target the DEC-205 protein. This protein is a cell surface receptor that is expressed on a variety of immune cells, including dendritic cells, macrophages, and B cells. The antibody is a biosimilar, meaning it is highly similar to an already approved and marketed antibody, making it a cost-effective and safe option for therapeutic use.

Structure

Oberotatug Biosimilar – Anti-DEC-205 mAb – Research Grade is a recombinant, fully humanized IgG1 antibody. It is composed of two heavy chains and two light chains, each containing constant and variable regions. The variable regions are responsible for binding to the DEC-205 protein, while the constant regions determine the antibody’s effector functions. The antibody has a molecular weight of approximately 150 kDa and a half-life of around 21 days in humans.

The antibody is produced using recombinant DNA technology, where the gene encoding for the variable regions is inserted into a host cell, such as Chinese hamster ovary (CHO) cells. The cells then produce large quantities of the antibody, which is then purified and formulated for therapeutic use.

Activity

Oberotatug Biosimilar – Anti-DEC-205 mAb – Research Grade has a high specificity and affinity for the DEC-205 protein, making it an effective therapeutic agent. When the antibody binds to the DEC-205 protein, it triggers a cascade of events that lead to the activation of the immune system. This includes the activation of dendritic cells, which are responsible for initiating and coordinating immune responses.

The antibody has been shown to enhance antigen presentation, leading to the activation of T cells and the production of cytokines, which are important mediators of the immune response. It also has the ability to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which can help to eliminate target cells expressing the DEC-205 protein.

Application

Oberotatug Biosimilar – Anti-DEC-205 mAb – Research Grade has potential applications in various therapeutic areas, including cancer, autoimmune diseases, and infectious diseases. Its ability to activate the immune system and enhance antigen presentation makes it a promising candidate for cancer immunotherapy. It has also shown promising results in preclinical studies for the treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, where it can help to regulate the immune response and reduce inflammation.

In infectious diseases, the antibody can be used to target pathogens that express the DEC-205 protein, such as viruses and bacteria. By binding to these pathogens, the antibody can enhance their uptake by dendritic cells, leading to a more robust immune response and potentially aiding in the clearance of the infection.

Conclusion

Oberotatug Biosimilar – Anti-DEC-205 mAb – Research Grade is a promising therapeutic agent with a well-defined structure and mechanism of action. Its high specificity and affinity for the DEC-205 protein make it an effective tool for activating the immune system and targeting various diseases. With ongoing research and clinical trials, this biosimilar antibody has the potential to become a valuable addition to the arsenal of therapies available for treating a range of diseases.